Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
ADG206 is an activatable prodrug form of a fully human monoclonal antibody (mAb) of the
immunoglobulin G1 (IgG1) subclass that specifically targets cluster of differentiation 137
(CD137) (also known as 4-1BB) as a co-stimulatory receptor agonist for the treatment of
advanced malignancies.